1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
ML/AI Tools to Advance Genomic Translational Research (MAGen) is sponsored by National Human Genome Research Institute (NHGRI). NHGRI aims to set up a research Consortium to collaboratively explore the feasibility of developing Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest di…
Get alerted about grants like this
Get emailed when new opportunities from “National Human Genome Research Institute (NHGRI)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ML/AI Tools to Advance Genomic Translational Research (MAGen) Funded Programs and Projects ML/AI Tools to Advance Genomic Translational Research (MAGen) Contributing NIH Institutes: National Human Genome Research Institute (NHGRI) National Institute on Aging (NIA) Office of Data Science and Strategy (ODSS) The need for increased research to develop tools to translate genomic research findings into clinical applications has been highlighted by NHGRI-convened workshops.
ML/AI techniques have successfully identified novel patterns in non-genomic clinical datasets, receiving FDA approval for ML/AI-enabled medical devices in fields such as radiology, cardiology, and various other disciplines of medicine. Vast amounts of multimodal data are available through advances in FAIR sharing standards and policies, facilitating the potential of using ML/AI approaches in translational genomics.
There is a need to utilize advances in technologies to translate genomic research findings into tools for potential future clinical applications that is we need tools that bridge basic and implementation research referred to in this initiative as, genomics translational research tools developed with disease expert involvement from the design through development and testing.
Maximizing the potential of ML/AI requires thoughtful attention to the ethical, legal, and social implications (ELSI) of its use in genomic medicine and healthcare more broadly. The long-term vision for successful tools would be to test them in clinical implementation settings.
NHGRI aims to establish a research Consortium, ML/AI Tools to Advance Genomic Translational Research (MAGen), to collaboratively explore the feasibility of Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease.
The ML/AI tools will leverage existing multimodal genomic and non-genomic data and will be cross validated in genomic translational research settings to ensure the robustness and generalizability of the tools for translational purposes.
Importantly, the Consortium will explore the ethical, legal, and social implications (ELSI) of integrating ML/AI tools into genomic medicine through the establishment of an ELSI Framework for their development, and through implementation of ELSI research projects.
The Consortium will compose of MAGen Development Sites with multi-disciplinary teams to develop the ML/AI tools and the MAGen Coordinating Center which will be responsible for technical, scientific, and administrative coordination activities to support the Consortium research activities including development of Consortium wide plans, coordinated ELSI-informed ML/AI tool development and cross validation, and dissemination of the developed resources.
From the September 18th, 2023, NHGRI Advisory Council Meeting Concept Clearance Presentation Frequently Asked Questions RFA-HG-24-004 : ML/AI Tools to Advance Genomic translational Research (MAGen) – Development Sites (UG3/UH3, Clinical Trials Not Allowed) Application Due Dates: July 26, 2024| Expiration Date: July 29, 2024 RFA-HG-24-005 : ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/UH3, Clinical Trials Not Allowed) Application Due Dates: July 26, 2024 Expiration Date: July 29, 2024 Related Funding Announcements: Office of Genomic Data Science Division of Genomics and Society Scientific Program Analyst Division of Genome Sciences Division of Neuroscience (DN) Health Data Scientist for AI Ethics Integrated Infrastructure and Emerging Technologies (IIET) Last updated: March 11, 2025
According to the current listing, eligibility includes: Eligible applicants include various types of non-profit organizations, educational institutions, government entities, and small businesses. Confirm the full requirements in the official notice before applying.
ML/AI Tools to Advance Genomic Translational Research (MAGen) is funded by National Human Genome Research Institute (NHGRI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional is sponsored by National Human Genome Research Institute (NHGRI). This limited competition NOFO supports transdisciplinary ELSI research addressing timely, complex, and understudied topics associated with advances in human genetics and genomics. It specifically aims to establish ELSI research teams that include partnerships with relevant communities affected by and with an interest in the proposed research, research capacity building, and workforce development opportunities for early career scholars and research team members. Eligible applicants are domestic organizations located in the United States and its territories that received less than $30 million per year in total NIH funding for the past three fiscal years, and are underrepresented among those receiving NHGRI funding for ELSI research.
Limited Competition: Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional is sponsored by National Human Genome Research Institute (NHGRI). This NOFO is a limited competition to support transdisciplinary ELSI research, establish ELSI research teams that include partnerships with relevant communities, build research capacity, and develop the ELSI workforce. It specifically aims to broaden the knowledge, skills, expertise, and perspectives in ELSI research and encourages engagement with communities affected by and interested in the research.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
This initiative will stimulate and support innovative research by small business concerns that may lead to the development of novel technologies for the early diagnosis, monitoring and treatment of micro and macro vascular complications of diabetes which are associated with significant morbidity and mortality of the disease and high costs to the health care system. Funding Opportunity Number: PA-14-058. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL.
While headlines chase AI and defense money, USDA's National Institute of Food and Agriculture runs a tight summer competitive cycle — Equipment Grants (June 25), Agricultural Genome to Phenome (June 29), New Beginning for Tribal Students (July 2), and Crop Protection and Pest Management (July 6). Here is how the four programs fit together, who is eligible, and why the land-grant system has a structural edge.
Read articleThe STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read articleThe Complement-ARIE program funds seven technology centers to develop human-based models that complement animal research. What it means for drug developers, academic researchers, and the regulatory pipeline.
Read article